Whitehawk Therapeutics

Whitehawk Therapeutics’ ADC portfolio consists of three assets designed to target proteins that are clinically validated and broadly expressed in high-potential cancer indications, including lung and ovarian.

The page discusses challenges in antibody drug conjugate (ADC) development for cancer treatment.

Aadi Bioscience warns that people have posed as its human resources representatives and hiring managers, and says it never requires candidates to pay during recruitment.

Whitehawk Therapeutics is an antibody drug conjugate (ADC)-focused oncology therapeutics company that employs an agile and pragmatic strategy to drug development.

Contact Whitehawk Therapeutics via email or phone.

Whitehawk Therapeutics combines breakthroughs in tumor targeting with leading ADC technologies and focused clinical strategies to efficiently deliver improved ADC therapies for people living with difficult-to-treat cancer.

Whitehawk Therapeutics outlines its privacy program, including the collection, use, and protection of personal information.

Aadi Bioscience, Inc. has a privacy program and a chief privacy officer. Its privacy statement describes the personal information it may collect, how it uses it, and how it protects it.

Aadi Bioscience, Inc. states that using its website means agreeing to its terms of use and applicable laws and regulations.

Whitehawk Therapeutics finalizes the sale of its Aadi Subsidiary to Kaken Pharmaceuticals for **$100 million in cash plus adjustments**, marking the completion of its strategic transformation. The oncology-focused company applies advanced technologies to develop cancer treatments. The transaction follows an earlier announcement of the planned divestiture.

Mar 2025PR NewswireNews article

Whitehawk Therapeutics (formerly Aadi Bioscience) rebrands to emphasize its shift toward developing antibody-drug conjugate (ADC) therapies. The company now prioritizes accelerating its portfolio with a focus on speed, agility, and precision in drug development. This transition aligns with its strategic evolution into a specialized ADC-focused biotech firm.

Mar 2025PR NewswireNews article

Aadi Bioscience secures a $100 million PIPE financing round to advance oncology therapeutics. The funding includes participation from new investors like OrbiMed, Invus, and Kalehua Capital, alongside Ally Bridge Group leading the placement. Tae Han, co-founder of Profoun, also joins as an investor. The company develops cancer treatments using established tumor biology and advanced delivery technologies.

Mar 2025PR NewswireNews article

Aadi Bioscience secures an exclusive license for a three-asset antibody-drug conjugate (ADC) portfolio developed collaboratively by WuXi Biologics and Hangzhou DAC. The company also completes a $100 million sale of its FYARRO® asset and raises $100 million in private investment in public equity (PIPE) financing. These moves mark a strategic shift for Aadi Bioscience in expanding its ADC pipeline.

Dec 2024BioSpaceNews article